---
title: Investors | Orasis Pharmaceuticals
description: Orasis Pharmaceuticals is backed by Arboretum Ventures, Johnson & Johnson Innovation (JJDC), Visionary Ventures, Sequoia Capital, and other investors.
image: https://orasis-pharma.com/hubfs/raw_assets/public/orasis-website/images/home-hero-bg.jpg
---
[Skip to content](https://orasis-pharma.com/investors#main-content)
[ ](https://orasis-pharma.com?hsLang=en)
- [ About ](https://orasis-pharma.com/about?hsLang=en)
#### [Company Overview Our mission, vision, and story](https://orasis-pharma.com/about?hsLang=en)
#### [Leadership Team Meet the executives driving our vision](https://orasis-pharma.com/leadership?hsLang=en)
#### [Board of Directors Guidance from industry leaders](https://orasis-pharma.com/board?hsLang=en)
#### [Investors Our partners in innovation](https://orasis-pharma.com/investors?hsLang=en)
- [ Qlosi ](https://orasis-pharma.com/qlosi?hsLang=en)
- [ Presbyopia ](https://orasis-pharma.com/presbyopia?hsLang=en)
- News
[Press Releases](https://orasis-pharma.com/press-releases?hsLang=en) [In the Media](https://orasis-pharma.com/in-the-media?hsLang=en)
- [Contact](https://orasis-pharma.com/contact?hsLang=en)
[Qlosi.com](https://qlosi.com?hsLang=en)
Our Partners
# Our Investors
## Investors
Orasis is funded by a diverse group of sophisticated investors with proven track records in the healthcare space.
In October 2024, Orasis announced a Series D financing co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC, Inc.
### Arboretum Ventures
Arboretum Ventures, LLC (“Arboretum”) is a venture capital firm, founded in 2002, specializing in the healthcare sector. The firm has raised $1 billion in capital across its funds with the most recent Fund VI closing in 2023 at $268 million. Arboretum focuses on capital-efficient investment opportunities in medical devices, life science tools & diagnostics, tech-enabled care delivery, and pharma adjacencies. Arboretum’s guiding vision is to identify transformative healthcare companies developing novel solutions to significant healthcare issues that simultaneously reduce cost and improve outcomes.
### Johnson & Johnson Innovation – JJDC
Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson. JJDC pursues opportunities to solve critical healthcare needs. JJDCs’ portfolio companies benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation.
### Catalio Capital Management
Catalio Capital Management, LP, is a multi-strategy healthcare and life sciences investment firm focusing on breakthrough companies developing the next generation of drugs, devices, diagnostics, and data-driven insights. Catalio’s exclusive network includes over 44 world-renowned scientists with extensive academic and scientific achievements who have each started well-established companies based on their research. Catalio has offices in New York and London.
### Visionary Ventures
Visionary Ventures is a later-stage venture fund focused on investing in drugs and devices for the eye. Visionary employs a unique approach to venture investing by partnering with over 40 key opinion leader ophthalmologists, as well as other sophisticated investors and industry professionals.
### Bluestem Capital
With more than 95 years of collective experience, Bluestem Capital is a private equity and venture capital firm with 25 portfolio companies. Healthcare is a leading investment area for the firm, with continued emphasis on eyecare innovation.
### SBI (Japan) Innovation Ventures
SBI (Japan) Innovation Fund is a biopharma focused venture capital fund that invests in Israeli venture-backed biopharma companies with cutting-edge science.
### Sequoia Capital
Sequoia Capital is a global venture capital firm focusing on the technology and healthcare industry.
### LifeSci Venture Partners
LifeSci Venture Partners is the venture investing arm of LifeSci Partners, a unique life sciences and healthcare consultancy.
### Maverick Ventures Israel
Maverick Ventures Israel invests in Israeli companies with cutting edge innovations.
## Get in Touch
Ready to see what's possible? Contact us here.
[Contact Us](https://orasis-pharma.com/contact?hsLang=en)
[ ](https://orasis-pharma.com/?hsLang=en)
An ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities.
#### Company
[Company Overview](https://orasis-pharma.com/about?hsLang=en) [Leadership Team](https://orasis-pharma.com/leadership?hsLang=en) [Board of Directors](https://orasis-pharma.com/board?hsLang=en) [Investors](https://orasis-pharma.com/investors?hsLang=en)
#### Product
[About Qlosi](https://orasis-pharma.com/qlosi?hsLang=en) [About Presbyopia](https://orasis-pharma.com/presbyopia?hsLang=en) [Qlosi.com](https://qlosi.com?hsLang=en)
#### News & Contact
[Press Releases](https://orasis-pharma.com/press-releases?hsLang=en) [In the Media](https://orasis-pharma.com/in-the-media?hsLang=en) [Contact Us](https://orasis-pharma.com/contact?hsLang=en) [info@orasis-pharma.com](mailto:info@orasis-pharma.com)
©2026 Orasis Pharmaceuticals, Inc. All Rights Reserved. QLOSI®, Orasis Pharmaceuticals, the Orasis Pharmaceuticals logo, and certain other trademarks herein are trademarks of Orasis Pharmaceuticals, Inc.
[Privacy Policy](https://orasis-pharma.com/privacy-policy?hsLang=en) [Terms of Service](https://orasis-pharma.com/terms-of-service?hsLang=en) [Health Data Privacy](https://orasis-pharma.com/health-data-privacy-policy?hsLang=en)
```json
{
"@context" : "https://schema.org",
"@id" : "https://www.orasis-pharma.com/#organization",
"@type" : "Organization",
"address" : {
"@type" : "PostalAddress",
"addressCountry" : "US",
"addressLocality" : "Ponte Vedra",
"addressRegion" : "FL",
"postalCode" : "32081",
"streetAddress" : "203 Fort Wade Rd., #140"
},
"contactPoint" : {
"@type" : "ContactPoint",
"contactType" : "customer service",
"email" : "info@orasis-pharma.com",
"telephone" : "+1-866-672-7471"
},
"description" : "Orasis Pharmaceuticals is an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, developer of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults.",
"logo" : "https://qlosiecp.com/hubfs/HQ%20Only/Orasis_Pharmaceuticals_Logo_RGB.svg",
"name" : "Orasis Pharmaceuticals",
"sameAs" : [ "https://www.linkedin.com/company/orasis-pharmaceuticals/", "https://twitter.com/OrasisPharma" ],
"url" : "https://www.orasis-pharma.com/"
}
```
```json
{
"@context" : "https://schema.org",
"@id" : "https://www.orasis-pharma.com/#website",
"@type" : "WebSite",
"name" : "Orasis Pharmaceuticals",
"publisher" : {
"@id" : "https://www.orasis-pharma.com/#organization"
},
"url" : "https://www.orasis-pharma.com/"
}
```